Hepatitis C, other infectious diseases, and drug-related harms

In programme

13 sessions 59 presentations View the programme

About

This track is co-produced by the International Network on Health and Hepatitis in Substance Users (INHSU).

This track focuses on reducing drug-related harms. It examines global progress towards hepatitis C elimination, and innovative models of care for improving the health and well-being of people who use drugs.

Hepatitis C, other infectious diseases, and drug-related harms

About

Sessions

Wednesday, 23 October

Enhancing access to harm reduction services in community and prisons: experiences of translating policy into practice and scaling interventions

Infectious diseases in people who inject drugs

Surveillance of drug-related morbidity and mortality

Drug use trends

Hepatitis C, HIV, and other drug related harms

Thursday, 24 October

Opioid Agonist Treatment: novel formulations and challenges

Understanding drug-related deaths

Understanding harm reduction: economic, social, and health perspectives

Hepatitis C testing and treatment

The hepatitis C endgame: Science, Policy, Politics

Viral hepatitis among people who inject drugs

Friday, 25 October

Intentional and non-intentional drug-related deaths

Overdose prevention

Presentations

Wednesday, 23 October

Enhancing scale-up of needle and syringe programs in the community in Sweden

Achieving high-coverage and retention in opioid agonist treatment in the community in Spain

Introduction and expansion of needle and syringe programs and opioid agonist treatment in prison in Moldova

Overdose prevention site development and delivery in Switzerland

How do we optimise and integrate the provision of harm reduction services in the community and prison?

Increased hepatitis C and HIV incidence among people who inject drugs in Montreal, Canada, 2011-2023

Decentralized consultation for infectious diseases with at-risk populations: preliminary results

Associations of alcohol consumption with long-term mortality of ART-naïve persons seeking HIV care.

“They kicked me out of hospital twice”: barriers and facilitators accessing care with an injecting-related infection

Acute drug-toxicity presentations involving crack cocaine to Euro-DEN Plus sentinel hospitals in Europe from 2014-2022

Mothers receiving substance use treatment involved in care proceedings: A record linkage cohort study

Mortality among first-time opioid agonist therapy patients in Austria, 2002-2021: A national retrospective cohort study

Drug poisoning deaths of under 30-year-olds – Key issues in the cause of death investigation documents

What are the reasons for injecting methadone? A qualitative study among people who inject drugs in Barcelona

Monitoring intravenous drugs use in Spain through syringe residue analysis

Codeine, oxycodone, and tramadol prescription prior to overdose deaths compared to toxicological findings

20-year trends in Australian methamphetamine-related deaths: An age–period–cohort–interaction analysis

STTBI risk reduction with OAT among people with prescription-type opioid use disorder

Are Australian pharmacists willing and prepared to offer Hepatitis C services? Findings from a representative sample

Looking under rocks: Skin infections in people who use drugs: a mixed-methods investigation in Wales

HCV antibody and RNA testing combined with nursing and peer-based outreach to enhance HCV testing and treatment among vulnerable groups

Prevalence and microelimination of Hepatitic C in intravenous drug users - improving linkage to care

Improving the model of care pathway for HCV between the drug care centres and their referral hospitals in Catalonia.

Adão e Eva II Project – HIV, Hepatitis and other STI’s prevention and screening among hard-to-reach populations

Thursday, 24 October

Long-acting injectable buprenorphine for opioid use disorder: key findings from a longitudinal qualitative study

Associations between opioid agonist therapy exposure and chronic pain characteristics among people who inject drugs

Adapting Opioid Therapy: Transition from Methadone to Slow-Release Morphine Amid COVID-19 Supply Chain Disruptions

Impact of long-acting depot buprenorphine post-release from custody– Early findings from the Release Study

A socio-ecological systematic review of harm reduction interventions addressing the U.S. opioid overdose epidemic

Drug-related mortality associated with gabapentinoid/Z-drug co-prescribing among opioid-agonist treatment recipients

Treatment pathways and transitions of young adults during opioid maintenance treatment

Policy Responses to Drug-Related Deaths: The power of numbers?

Effect of integrated smoking cessation treatment on smoking intensity among persons who receive opioid agonist treatment

High body mass index is prevalent in people with opioid use disorder in Northern England and increases risk of death

Homeless people and mental health: an observational study in an Emergency Shelter in Lisbon

An economic evaluation of Catalonia’s Needle Exchange Programme (NEP). Cost-Benefit analysis

A multisite implementation trial of collaborative care for Opioid Dependence: 3-month outcomes from the EPIC-MATOD trial

Drug-related deaths among housed and homeless individuals in the UK and the USA

Multi Parameter Estimation of Prevalence modelling: methods to estimate the prevalence of opioid dependence in Scotland

Endgames: Disease eliminations and their politics

Gender differences in the hepatitis C cascade of care

Are the key impacts being measured? Hepatitis C elimination in Australia

Crisis in the race to hepatitis C elimination: modelling futures without disease

Pilot HCV Birth Cohort Screening in UK Primary Care using a postal oral fluid home testing kit: the HEPCAPP StudyPP STUDY

Modelling the impact of scaling up of HCV case finding and treatment for people who inject drugs in England

A national program to scale-up decentralized HCV point-of-care testing and treatment in Australia

HCV Community-led monitoring: from consultation to effective policy contributions

Epidemiology of injecting drug use and injection related harms among people who are incarcerated

Towards elimination of hepatitis C in Oslo: cross-sectional prevalence studies in 2018, 2021, 2022 and 2023

Context specific factors that impact on the optimal scale up of hepatitis C testing and treatment in the UK

The development of a toolkit to support the elimination of viral hepatitis B and C in prisons

Friday, 25 October

Drug-induced deaths and non-fatal poisonings in youth – associations with ACE and psychiatric morbidity

Suicide in people prescribed opioid-agonist therapy (OAT) in Scotland, 2011-2020: a national retrospective cohort study.

Accidental versus intentional drug overdose deaths: a national register linkage study

Prevalence of Benzodiazepine Prescription Prior to Overdose Deaths Compared to Toxicological Findings

Who reports witnessing an opioid overdose? : Findings from the European naloxone outcome research study (NalPORS)

Are Take-Home Naloxone kits available at witnessed overdose events - a European Naloxone Outcome Research Study

Associations of alcohol consumption with long-term mortality of ART-naïve persons seeking HIV care. 